1-3 of 3
Patrick Chun, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Selectivity of T Cell Engager AMV564 Against Different Leukemic Blast Populations and Potential Application for Patient Selection

Aurelien Sarde, Sterling Eckard, PhD, Li Mei, Curtis Ruegg, PhD, Patrick Chun, MD, Victoria Smith, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-141475
Published: 2020
Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 834.
https://doi.org/10.1182/blood-2019-129042
Published: 2019
Journal Articles

A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

Mark D. Minden, MD PhD, Wendy Stock, MD, Howland Crosswell, MD, Robert D Siegel, MD, Patrick Chun, MD, Steve Abella, MD, Jing He, Clarence Eng, MPH, Dan Douer, MD
Journal: Blood
Blood (2015) 126 (23): 4866.
https://doi.org/10.1182/blood.V126.23.4866.4866
Published: 2015